MedCap AB (publ) (STO:MCAP)
Sweden · Delayed Price · Currency is SEK 561.00
+9.50 (1.72%)
Nov 4, 2026, 5:29 PM CET
MedCap AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,374 | 2,110 | 1,807 | 1,589 | 1,112 | 916.3 |
Revenue Growth | 18.59% | 16.73% | 13.74% | 42.96% | 21.30% | 11.80% |
Gross Profit Gross Profit Growth | 1,437 | 1,238 | 1,058 | 928.3 | 664.7 | 558.6 |
Operating Income Operating Income Growth | 386.9 | 288.7 | 240.8 | 216.2 | 149.1 | 103.8 |
Net Income Net Income Growth | 274.2 | 219.8 | 207.4 | 172.2 | 117.6 | 96.5 |
Earnings Per Share EPS Growth | 18.30 | 14.67 | 14.00 | 11.60 | 7.90 | 6.50 |
EPS Growth | 39.02% | 4.80% | 20.66% | 46.84% | 21.54% | 53.18% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Assistive Tech Assistive Tech Growth | 1,069 | 981.8 | 767.2 | 590.5 | 270 | - |
Medtech Medtech Growth | 752.3 | 689.6 | 607.7 | 511.7 | 444.3 | - |
Specialty Pharma Specialty Pharma Growth | 498.9 | 436.6 | 431.8 | 485.3 | 397 | 316.8 |
Revenue (Total) Revenue (Total) Growth | 2,321 | 2,108 | 1,807 | 1,587 | 1,111 | 916.3 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 272.8 | 370.4 | 370.1 | 188.2 | 236.2 | 139.7 |
Total Debt Total Debt Growth | 437.7 | 482.9 | 358 | 261.2 | 340 | 256.9 |
Net Cash (Debt) Net Cash Growth | -164.9 | -112.5 | 12.1 | -73 | -103.8 | -117.2 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -11.01 | -7.50 | 0.81 | -4.91 | -7.01 | -7.92 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 421.6 | 342.7 | 360 | 228 | 85.5 | 116.3 |
Capital Expenditures CapEx Growth | -24.7 | -25.7 | -41.8 | -22.1 | -26.3 | -45.3 |
Free Cash Flow Free Cash Flow Growth | 396.9 | 317 | 318.2 | 205.9 | 59.2 | 71 |
Free Cash Flow Growth | 35.18% | -0.38% | 54.54% | 247.80% | -16.62% | -31.66% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 60.52% | 58.67% | 58.52% | 58.42% | 59.80% | 60.96% |
Operating Margin | 16.30% | 13.69% | 13.32% | 13.61% | 13.41% | 11.33% |
Pretax Margin | 14.83% | 13.70% | 14.47% | 13.99% | 13.68% | 12.77% |
Profit Margin | 11.55% | 10.42% | 11.48% | 10.84% | 10.58% | 10.53% |
FCF Margin | 16.72% | 15.03% | 17.61% | 12.96% | 5.33% | 7.75% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.65 | 37.66 | 42.91 | 29.02 | 27.26 | 27.31 |
Forward PE | 24.62 | 31.55 | 39.28 | 25.95 | 25.95 | 25.95 |
P/FCF Ratio | 21.05 | 26.11 | 27.97 | 24.27 | 54.15 | 37.12 |
PS Ratio | 3.52 | 3.92 | 4.92 | 3.15 | 2.88 | 2.88 |